Andrew Mark Haydon
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Cancer Research top 1%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 98
- Cancer Immunotherapy and Biomarkers 35
- Cutaneous Melanoma Detection and Management 32
- CAR-T cell therapy research 17
- Colorectal Cancer Treatments and Studies 15
- Colorectal Cancer Screening and Detection 10
-
- Cancer Genomics and Diagnostics 11
- Co-authors
- Graham G. Giles (14 shared papers)Dallas R. English (12 shared papers)John Llewelyn Hopper (9 shared papers)Robert J. MacInnis (7 shared papers)Jeremy R. Jass (1 shared paper)Dorota M. Gertig (3 shared papers)Stuart Keith Roberts (2 shared papers)Wa Sham Cheung (1 shared paper)
- Journals
- Annals of Oncology (23 papers)European Journal of Cancer (15 papers)Journal of Clinical Oncology (9 papers)The Lancet Oncology (8 papers)British Journal of Cancer (7 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Andrew Mark Haydon
161 papers receiving 11.8k citations
Andrew Mark Haydon's Hit Papers
Peers
Comparison fields: 5 of 129
- Oncology 7.1k
- Cancer Research 2.1k
- Immunology 1.5k
- Pathology and Forensic Medicine 1.0k
- Biotechnology 378
Countries citing papers authored by Andrew Mark Haydon
This map shows the geographic impact of Andrew Mark Haydon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Mark Haydon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Mark Haydon more than expected).
Fields of papers citing papers by Andrew Mark Haydon
This network shows the impact of papers produced by Andrew Mark Haydon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Mark Haydon. The network helps show where Andrew Mark Haydon may publish in the future.
Co-authors
The 25 scholars most cited alongside Andrew Mark Haydon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 169 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Hit paper breakdown → | 2018 | 1503 |
| 2 | Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer Hit paper breakdown → | 2016 | 1170 |
| 3 | Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma Hit paper breakdown → | 2017 | 1143 |
| 4 | Investigation of the Safety of Irreversible Electroporation in Humans Hit paper breakdown → | 2011 | 389 |
| 5 | 2020 | 354 | |
| 6 | 2005 | 304 | |
| 7 | 2020 | 303 | |
| 8 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Hit paper breakdown → | 2021 | 296 |
| 9 | 2018 | 290 | |
| 10 | Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial Hit paper breakdown → | 2020 | 237 |
| 11 | Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma Hit paper breakdown → | 2022 | 215 |
| 12 | 2018 | 201 | |
| 13 | 2021 | 185 | |
| 14 | 2018 | 181 | |
| 15 | 2019 | 180 | |
| 16 | 2021 | 172 | |
| 17 | 2004 | 158 | |
| 18 | 2019 | 152 | |
| 19 | 2021 | 147 | |
| 20 | 2004 | 143 |
About Andrew Mark Haydon
Andrew Mark Haydon is a scholar working on Oncology, Cancer Research, Pathology and Forensic Medicine, Molecular Biology and Immunology, having authored 169 papers that have together received 12.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (35 papers), Cutaneous Melanoma Detection and Management (32 papers), Melanoma and MAPK Pathways (25 papers), CAR-T cell therapy research (17 papers), Colorectal Cancer Treatments and Studies (15 papers), Cancer Genomics and Diagnostics (11 papers), Colorectal Cancer Screening and Detection (10 papers) and Genetic factors in colorectal cancer (9 papers). The work is most often cited by research in Oncology (7.1k citations), Cancer Research (2.1k citations), Immunology (1.5k citations), Pathology and Forensic Medicine (1.0k citations) and Biotechnology (378 citations). Andrew Mark Haydon has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Graham G. Giles, Dallas R. English, John Llewelyn Hopper, Robert J. MacInnis, Jeremy R. Jass, Dorota M. Gertig, Stuart Keith Roberts, Wa Sham Cheung, Catriona McLean and Peter M. Evans. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.